Literature DB >> 27671902

Neurodegeneration in multiple sclerosis and neuromyelitis optica.

Izumi Kawachi1, Hans Lassmann2.   

Abstract

Multiple sclerosis (MS) and neuromyelitis optica (NMO) are autoimmune demyelinating diseases of the central nervous system (CNS), having distinct immunological and pathological features. They have two pathogenic components, 'inflammation' and 'neurodegeneration', with different degrees of severity and pathogenetic mechanisms. The target antigen of autoimmunity in NMO is the water channel aquaporin-4 (AQP4), and antibodies directed against this antigen result in astrocyte damage. MS is a disease primarily affecting myelin and oligodendrocytes, but thus far, no MS-specific autoantigen has been identified. The distinct inflammatory processes in these diseases may trigger cascades of events leading to disease-specific neurodegeneration. Damage of the CNS tissue appears to be amplified by mechanisms that are in part shared by the two conditions and involve oxidative burst activation in microglia/macrophages, mitochondrial damage and axonal energy failure, Wallerian degeneration and meningeal inflammation. However, they appear to differ regarding the nature of the inflammatory response, the type and extent of cortical injury, and the type of astrocyte reaction and damage. Here, we provide a detailed comparison of the pathology between MS and NMO, which may help to define shared and disease-specific mechanisms of neurodegeneration in these diseases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROPATHOLOGY

Mesh:

Year:  2016        PMID: 27671902     DOI: 10.1136/jnnp-2016-313300

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  62 in total

1.  Altered neurovascular coupling in neuromyelitis optica.

Authors:  Xi Guo; Jiajia Zhu; Ningnannan Zhang; Linjie Zhang; Yuan Qi; Huanhuan Cai; Xue Zhang; Jie Sun; Qiuhui Wang; Li Yang; Fu-Dong Shi; Chunshui Yu
Journal:  Hum Brain Mapp       Date:  2018-10-13       Impact factor: 5.038

2.  Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder.

Authors:  Yaou Liu; Di Dong; Liwen Zhang; Yali Zang; Yunyun Duan; Xiaolu Qiu; Jing Huang; Huiqing Dong; Frederik Barkhof; Chaoen Hu; Mengjie Fang; Jie Tian; Kuncheng Li
Journal:  Eur Radiol       Date:  2019-02-15       Impact factor: 5.315

3.  Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis.

Authors:  Rodrigo B M Silva; Samuel Greggio; Gianina T Venturin; Jaderson C da Costa; Marcus V Gomez; Maria M Campos
Journal:  Mol Neurobiol       Date:  2018-04-17       Impact factor: 5.590

4.  ERβ-selective agonist alleviates inflammation in a multiple sclerosis model via regulation of MHC II in microglia.

Authors:  Xi Liu; Jing Deng; Rong Li; Changhong Tan; Hongli Li; Zhong Yang; Lifen Chen; Yangmei Chen; Xinjie Tan
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 5.  Differential contribution of microglia and monocytes in neurodegenerative diseases.

Authors:  Caroline Baufeld; Elaine O'Loughlin; Narghes Calcagno; Charlotte Madore; Oleg Butovsky
Journal:  J Neural Transm (Vienna)       Date:  2017-10-23       Impact factor: 3.575

6.  Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.

Authors:  Antonio Barreiro-González; Maria T Sanz; Sara Carratalà-Boscà; Francisco Pérez-Miralles; Carmen Alcalá; Enrique España-Gregori; Bonaventura Casanova
Journal:  Acta Neurol Belg       Date:  2020-10-12       Impact factor: 2.396

Review 7.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

Review 8.  Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

Authors:  Floriana De Angelis; Domenico Plantone; Jeremy Chataway
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

9.  Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.

Authors:  Yair Mina; Shila Azodi; Tsemacha Dubuche; Frances Andrada; Ikesinachi Osuorah; Joan Ohayon; Irene Cortese; Tianxia Wu; Kory R Johnson; Daniel S Reich; Govind Nair; Steven Jacobson
Journal:  Neuroimage Clin       Date:  2021-04-28       Impact factor: 4.881

10.  Demyelination and remyelination detected in an alternative cuprizone mouse model of multiple sclerosis with 7.0 T multiparameter magnetic resonance imaging.

Authors:  Shuang Ding; Yu Guo; Xiaoya Chen; Silin Du; Yongliang Han; Zichun Yan; Qiyuan Zhu; Yongmei Li
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.